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ABSTRACT 
The aim of the present study was to develop oral multiparticulate pulsatile drug delivery system for hypoglycemic agent ‘glipizide’. Time dependent 
rupturable system was selected for delivering glipizide in a pulsatile pattern. In the present study, two types of particles were prepared i. e. Type 1 
(immediate release type) and Type 2 (delayed release type). Extrusion and spheronization process was selected to prepare particles, wherein 
lactose and microcrystalline cellulose mixture (2:1) was used as processing aid. Various parameters of extrusion and spheronization process were 
optimized in order to meet desired particle size distribution, shape and flow properties. Immediate release Type 1 particle was optimized to achieve 
more than 80% drug release within 30 min for which surfactant approach was employed to overcome the dissolution rate related issue of the 
glipizide. Delayed release pattern of Type 2 particles was achieved by coating hydroxypropylmethylcellulose and ethyl cellulose. Various coating 
parameters were optimized to attain efficient coating of the particles. Different concentrations of hydroxypropylmethylcellulose (5 and 3.5% w/w 
E-15 grade) and ethyl cellulose (5 and 3% w/w) were studied for release pattern for Type 2 particles. Final formulation was characterized using for 
particles size, flow properties and surface morphology. To examine the drug release, dissolution studies were performed. Pharmacokinetics studies 
in Sprague Dawley rats reveal improved oral bioavailability of glipizide following oral administration.  
Keywords: Pulsatile delivery, Glipizide, Immediate release, Delayed release, Oral administration, Pharmacokinetic study. 
 
INTRODUCTION 
Diabetes mellitus (DM) is a group of diseases marked by high levels 
of blood glucose resulting from defects in insulin production, insulin 
action, or both. Diabetes can lead to serious complications and 
premature death, but people with diabetes can take steps to control 
the disease and lower the risk of complications. Type 1 DM account 
for 5 to 10 percent of all diagnosed cases of diabetes. Risk factors for 
Type 1 diabetes may be autoimmune, genetic, or environmental. 
Type 2 DM (non-insulin dependent diabetes mellitus) is 
characterized by high blood glucose in the context of insulin 
resistance and relative insulin deficiency [1]. 
Oral sulfonylurea’s therapy remains a cornerstone for the treatment 
of diabetes. Sulfonylurea’s acts through insulin release by inhibiting 
the KATP 
Most widely used hydrophobic polymer in pharmaceutical film 
coating is ethyl cellulose (EC) due to its easy film forming nature, 
negligible toxicity and better physicochemical properties. EC is a 
best option for modified release coating [10]. To control the drug 
release from the formulation, polymers are used in combination 
with secondary polymer such as hydroxypropyl methylcellulose 
(HPMC). HPMC is hydrophilic in nature and alters its structure by 
virtue of pores and channels. Due to this property, drug molecule 
can diffuse out easily to control the release properties [11]. To 
prevent cracking of film and efficient film formation, plasticizers are 
used in EC containing formulations [12]. Moreover, plasticizers act 
as channeling agent through which drug release occur [13]. Thus, 
aim of the present investigation is to develop and in vitro- in vivo 
evaluation of novel glipizide loaded multiunit pulsatile formulation 
using HPMC and EC polymers by wurster process.  
channel of the pancreatic β-cells [2]. Glipizide is a second 
generation sulfonylurea act by stimulating the release of insulin 
from the pancreas e reducing blood glucose level in humans [3]. 
Owing to its short biological half life (3-5h), there is an urgent need 
of such a delivery system which can overcome its multidosing per 
day through delayed release and extended half life. Thus, 
development of multiunit pulsatile dosage form would be the best 
option and advantageous. Various researchers have developed 
glipizide formulations by different methods [4-8]. Multiunit pulsatile 
dosage form can be prepared using various polymers and 
combination of polymers to control the release of the drug through 
wurster process [9].  
 
 
Fig. 1: Mechanism of drug release 
 
MATERIALS AND METHODS 
Materials  
Glipizide was obtained as a kind gift sample provided by Supra 
chemicals, Mumbai and Consern Pharma, Ludhiana Punjab. 
Hydroxypropylmethylcellulose and Polyvinylpyrrolidone were 
obtained from Signet, Mumbai (India). Ethyl cellulose was obtained 
from Rohm, Germany. Methanol and other chemicals were obtained 
from Loba Chemie, Mumbai, India. All other chemicals were of 
analytical grade.  
Preparation of Type 1 (immediate release) and Type 2 particles 
(delayed release) 
The required quantity of drug and excipients was mixed in a pestle 
and mortar. Type 1 particles was prepared by extrusion and 
spheronization. Subsequently, these particles were evaluated for 
various parameters like particle size distribution by sieving, flow 
properties and friability. Type 2 particles were prepared by coating 
optimized Type 1 particles using Mini Glatt coater (Germany). Type 
1 particles was coated initially with HPMC E-15 followed by EC 
polymer to obtain the Type 2 particles. The coating process was 
optimized to obtain a desired release pattern. Type 1 and Type 2 
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particles were then mixed in a proper proportion to obtain a 
pulsatile release profile with a lag period of 6-8 h. 
Characterization of Type 1  
Particles size analysis 
Particle size analysis was performed by mechanical sieving using 
sieves of different sieve number (18, 28, 40, 60 and 100). The plot of 
sieve number vs. Percent particle by weight retained on each sieve 
was plotted. Correlation between the particle diameter and sieve 
number is given in Table 1. 
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Flow ability  
Flow ability was assessed by measuring angle of repose and Carr’s 
Index (CI). Angle of repose and tap density were measured by using 
granulator tester and tap density tester, respectively [14]. Mean of 
six determinations was reported. The CI was calculated from bulk 
and tap densities. 
Tan α = Height 0.5 ∗ Base        … … … … . …� (1) 
CI = Tapped density−Bulk density
Tapped density
∗ 100   ….   (2) 
Friability test 
10 g particles were weighed and friability test was performed by 
using Roche friabilator up to 100 counts. 
Evaluation of final formulation 
Dissolution studies  
Final pulsatile release formulation was prepared by combining Type 
1 and Type 2 particles in proper proportion. Type 2 particles were 
selected based on the release profile obtained previously. Final 
formulation was prepared by mixing the Type 1 and Type 2 particles 
equivalent to 5 mg of drug, respectively. 
Pharmacokinetic studies 
Pharmacokinetic study was carried out to determine the oral 
bioavailability of glipizide formulation. For in vivo pharmacokinetic 
study, male S. D. rats weighing 250–300 g (n=4) were used as per 
IAEC approved protocol number IAEC/10/72. Animals were kept on 
fasting overnight before start of experiment. Glipizide suspension in 
sodium CMC (2.5% w/v) at a dose of 5 mg/kg body weight, and final 
formulation with dose of 5 mg/kg of body weight was orally 
administered to rats with the help of oral gavage.  
Blood samples (0.5 ml) were collected from the retro-orbital plexus 
under mild ether anesthesia into heparinized microcentrifuge tubes 
(containing 20 μl of 1000 IU heparin/ml of blood). Blood samples 
were collected at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 h. After 
each sampling, 1 ml of normal saline was administered to prevent 
changes in the central compartment volume.  Plasma was separated 
by centrifuging the blood samples at 10000 g for 10 min, at 15°C.  
To 200 μl of plasma, 50 μl of tolbutamide (10 µg/ml) and methanol 
(500μl) were added and vortexed for 5 min. Finally, it was 
centrifuged at 10,000 g for 10 min and organic layer was separated 
which contained glipizide and tolbutamide. Supernatant was 
collected and analyzed using validated HPLC bioanalytical method. 
RESULT AND DISCUSSION 
Preparation and characterization of Type 1 and Type 2 particles 
Optimized parameters for preparation of Type 1and Type 2 particles 
are given in Table 2 and 3 respectively. For preparation of Type 2 
particles, Type 1 particles were coated with optimized 
concentrations of 3.5 and 2% w/v of HPMC and EC, respectively. 
Optimized formula for Type 1 particles is presented in Table 4.  
 
Table 2: Process parameter for extrusion and spheronization 
Parameter Value 
Volume of binder solution 12 ml 
Concentration of binder solution 2% w/v 
Speed of extruder 50% 
Speed of spheronizer 3000 rpm 
Spheronization time 5 min 
Time for drying 2 h 
 
Table 3: Optimized parameters for film coating process 
Parameter HPMC EC 
Inlet air temperature 600 40C  0C  
Feed solution concentration 3.5% w/v  2% w/v  
Flow rate 1.5 ml/min  1.5 ml/min 
Fluidization pressure 0.22 MPa 0.22 MPa  
Atomization pressure 0.32 MPa  0.31 MPa  
 * Batch size - 5 g 
 
Table 4: Optimized formula for Type 1 particles 
Name of the ingredient % Quantity 
Glipizide 3% 
Microcrystalline cellulose 31% 
Lactose 62% 
SLS 3% 
Binder solution (2% w/v) PVP 12% 
 
Characterization  
Particles size distribution  
Particle size distribution analysis was performed using sieving 
method. Type 1 particles exhibited maximum retention on the sieve 
number 28. While, Type 2 particles prepared with 20%w/w HPMC 
and 5%w/w EC showed that the 80 % particles were retained on the 
sieve number 22 indicating an increase in the particle size of 
particles after coating which is indicative of good coating efficiency. 
The values of CI and angle of repose showed excellent flow 
properties. Particle size distribution data are presented in Figure 2. 
Flow properties 
To examine the flow properties, angle of repose, Carr’s index, 
Hausner ratio and friability were measured. Angle of repose for 
Type 1 and Type 2 particles was 27 and 17.5°, respectively. This is 
indicative of good flow properties. Type 1 and Type 2 particles 
exhibited 14.31 and 9.52% Carr’s index, respectively. Hausner ratio 
and friability were well within the limits of good flow behavior.  
Surface morphology analysis 
Type 1 particles (uncoated glipizide particles) micrograph is 
presented in Figure 3A. Coating imperfections were observed on 
particles as indicated by the rough surface. Smooth surface with 
minimum imperfections was observed with particles coated with the 
20% HPMC and 5% EC as shown in Figure 3B. The Figure 3C is the 
cross sectional image of Type 2 particles showing the two distinct 
layer of coated polymers. Type 1 particles surface was found to be 
rough due to the imperfections and nature of the excipients used to 
prepare the particles while in case of Type 2 particles surface was 
found to be smooth due to coating of EC which indicates the efficient 




Fig. 2: Particle size distribution data 
 
 
Fig. 3: SEM micrographs of (A) Type 1 particles (B) Type 2 
particles (C) Cross section of Type 2 particles 
 
Dissolution studies 
To perform in vitro dissolution studies, phosphate buffer pH 6.8 was 
employed as release media. The release pattern of the final 
formulation showed 50% of drug released within first hour and 
remaining 50% drug released after a lag time of 7-8 h. Considering 
the cumulative release of the drug, it was observed that a release 
was more of delayed type. This is because of rate retarding property 
of the HPMC where drug release mechanism involves both diffusion 
through polymer and dissolution of polymer. Percent drug release 
vs. time profile is presented in Fig.4. 
 
 
Fig. 4: Percent drug release vs. time profile 
 
In vivo pharmacokinetic studies 
As in the case of diabetes mellitus there is increase in blood glucose 
level after taking the meal, to lower down the glucose level we need 
such a delivery system which can release the drug at a desired time 
point. To fulfill this requirement, pulsatile delivery is better option 
to release the drug immediately and after a delayed time period. In 
the market, immediate and sustained release formulations are 
available but these are having problems like pancreatic 
dysfunctioning and patient noncompliance due to higher dosing 
frequency. Hence to assure in vivo performance of formulation, 
pharmacokinetic study was carried out to study the release pattern 
of final formulation. Plasma concentration of glipizide loaded 
particles (5 mg/kg of each of Type 1 and Type 2 particles) after oral 
administration was compared with plasma concentration of 
glipizide suspension (5 mg/kg). The plasma concentration-time 
profile of glipizide loaded particles, and glipizide suspension is 
shown in Figure 6. The area under the curve (AUC) was calculated 
by trapezoidal method from Kinetica 5.0 software. The relevant 
pharmacokinetic parameters such as Cmax, tmax and AUC total
 
Fig. 5: HPLC chromatograph of internal standard and glipizide 
 
 are 
represented in Table 5.  
Pharmacokinetic study showed that 50% of drug released within 1 h 
and second dose released after a lag time of 6 h which confirms the 
pulsatile release pattern of the formulation. On the basis of 
pharmacokinetic studies results it is concluded that this pulsatile 




Fig. 6: Comparative in vivo plasma concentration- time profile of 
a) Glipizide loaded formulation and b) Glipizide suspension after 
oral administration (all values are reported in mean ±SD, n=4
Singh et al. 




Table 5: Pharmacokinetic parameters for glipizide suspension and formulation 
Formulation studied Dose (mg/kg) Cmax t(µg/ml) max1 and tmax2 AUC (min) total (µg min/mL) 
Glipizide suspension 5 3300 240 36610.7 
Glipizide loaded particles 5+5 3300 and 3600 240 and 720 70743.6 
 
CONCLUSION  
Present study is focused on the multiunit pulsatile delivery system 
for glipizide for treatment of diabetic patients. Type 1 particles were 
prepared by extrusion- spheronization process and characterized 
for particles size distribution, flow properties and surface 
morphology. Particles size analysis showed maximum retention at 
sieve no. 28 and 22 for Type 1 and Type 2 particles, respectively. 
Particles were of free flowing in nature as evidenced by flow 
properties outcomes. Surface morphology showed a rough surface 
for Type 1 particles and smooth surface for Type 2 particles after 
coating. In vitro release and in vivo pharmacokinetic studies of final 
formulation exhibited biphasic release pattern. Hence, it is 
concluded that the multiunit pulsatile delivery system could be one 
of the best option for the treatment of diabetes.  
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